← Home
Weight Loss
Metabolic regulation & adiposity
Common Stacks
2Lean Cut Fat-Loss Stack
ExperimentalTargeted fat loss with muscle preservation, without full GLP-1 dose escalation.
- Protocol
- AOD-9604 300 mcg SQ AM fasted + CJC/Ipa 100/200 mcg SQ PM fasted.
- Duration
- 8–12 weeks; pair with caloric deficit + resistance training.
- Notes
- Non-GLP-1 alternative. Stop AOD if persistent fatigue or hypoglycemia.
CagriSema (GLP-1 + Amylin)
ClinicalMaximize weight loss while reducing GI side effects of high-dose semaglutide alone.
- Protocol
- Semaglutide 2.4 mg + Cagrilintide 2.4 mg SQ once weekly (trial regimen).
- Duration
- Continuous; 4-week titration; reassess at 16 and 52 weeks.
- Notes
- Investigational Phase 3 protocol (REDEFINE-1, ~22% weight loss). Currently Rx-only via clinical trials.
12 peptides
FDA ApprovedGrade A
Semaglutide
Metabolic / GLP-1 Agonist
Type 2 DiabetesObesity
FDA ApprovedGrade A
Tirzepatide
Metabolic / GIP+GLP-1 Agonist
Type 2 DiabetesObesity
FDA ApprovedGrade A
Exenatide
Metabolic / GLP-1 Agonist
Type 2 Diabetes
FDA ApprovedGrade A
Liraglutide
Metabolic / GLP-1 Agonist
Type 2 DiabetesObesity
FDA ApprovedGrade A
Pramlintide
Metabolic / Amylin Analog
Type 1 DiabetesType 2 Diabetes (adjunct to insulin)
Research UseGrade C
AOD-9604
Metabolic / Lipolytic
Fat metabolismWeight management
FDA ApprovedGrade A
Tesamorelin
Endocrine / GHRH Analog
HIV-associated lipodystrophyVisceral fat reduction
Research UseGrade B
Retatrutide
Metabolic / Triple Agonist (GLP-1 + GIP + Glucagon)
ObesityType 2 Diabetes (investigational)
Research UseGrade B
Cagrilintide / CagriSema
Metabolic / Long-acting Amylin Analog
Obesity (investigational)
Research UseGrade B
Survodutide
Metabolic / GLP-1 + Glucagon Dual Agonist
ObesityMASH (investigational)
Research UseGrade B
Orforglipron
Metabolic / Oral Small-molecule GLP-1 Agonist
ObesityType 2 Diabetes (investigational)
Research UseGrade C
5-Amino-1MQ
Metabolic / NNMT Inhibitor
Fat lossMuscle preservation (research)